* Kinnate Biopharma Inc reported a quarterly adjusted loss of 36 cents per share for the quarter ended in December, higher than the same quarter last year, when the company reported EPS of -72 cents. The mean expectation of six analysts for the quarter was for a loss of 42 cents per share. Wall Street expected results to range from -50 cents to -37 cents per share.
* Reported revenue was zero; analysts expected zero.
* Kinnate Biopharma Inc's reported EPS for the quarter was a loss of 36 cents.
* The company reported a quarterly loss of $17.06 million.
* Kinnate Biopharma Inc shares had risen by 12.2% this quarter.
FORECAST CHANGES
* The mean earnings estimate of analysts was unchanged in the last three months.
* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell."
* Wall Street's median 12-month price target for Kinnate Biopharma Inc is $2.50
This summary was machine generated from LSEG data March 29 at 07:05 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Dec. 31 2023 -0.42 -0.36 Beat
Sep. 30 2023 -0.67 -0.65 Beat
Jun. 30 2023 -0.75 -0.68 Beat
Mar. 31 2023 -0.73 -0.73 Met
Comments